BURNABY, BC -- (Marketwired) -- 09/09/14

LED Medical Diagnostics Inc. (TSX VENTURE: LMD) (OTCQX: LEDIF) (FRANKFURT: LME) ("LED Medical" or "the Company") is pleased to announce the appointment of Jody Kelly, CPA, as Vice President of Finance. Mrs. Kelly will report to Dr. David Gane, CEO of LED Medical, and assume responsibility for the company's accounting, financial planning and analysis, cash flow management, internal auditing and GAAP compliance, public company reporting and treasury.

"We are excited that Jody has accepted the role as VP of Finance with LED Medical, as she is a high calibre financial executive with a wealth of insight and experience," stated Dr. David Gane, CEO. "In addition to her financial and accounting background, Jody has a depth of expertise in process design/compliance and internal control design - skills we will be able to leverage during the high rate of growth we anticipate as we continue to evolve LED Medical from a single product manufacturer to a comprehensive North American supplier of dental digital imaging technologies."

"I'm very pleased to join the leadership team at LED Medical," stated Mrs. Kelly. "It is such an exciting time of transition and growth for the company and I look forward to supporting its build out through exceptional financial management and reporting."

Prior to her appointment at LED Medical, Mrs. Kelly served from 2005 as Chief Financial Officer at Dialog Medical, LLC., a developer of medical consent software based in Atlanta, Georgia, where she established the company's accounting and financial operations from start-up phase through to established market player. From 1994 to 2005, Mrs. Kelly served as Controller at JGA Corporation, a building material distributor based in Doraville, Georgia, where she managed all financial functions for thirteen remote warehouses during sales growth from $50 million to $110 million. Mrs. Kelly has also served as an auditor for Atkinson & Pitts, an Atlanta-based accounting firm, from 1992 to 1994 and as a financial analyst for C.R. Bard, Inc., a medical device manufacturer based in Murray Hill, New Jersey from 1990 to 1992. She has a B.S. in Accounting (1986) from the University of Louisiana.

 About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX VENTURE) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

LED Dental Inc., a wholly-owned subsidiary, is backed by an experienced leadership team dedicated to a higher level of service and support. LED Dental offers advanced diagnostic imaging equipment that seamlessly integrates into dental practices. The Company is committed to providing dental practitioners with the best technology available by identifying and adding strong products to its growing portfolio. Additionally, the company manufactures the award-winning VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. The VELscope® Vx is now used to conduct more screenings for oral cancer and other oral mucosal diseases than any other adjunctive device. For more information, call 888.541.4614 or visit www.leddental.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2013. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations:
Beverly Brooks
Phone: 416 482 8889
Cell: 647 869 7205
E-Mail: brooks.communications@rogers.com